Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: an Open Label Pilot Study of Anticholinergic Agent vs. Mirabegron (MYRBETRIQ) to Evaluate Cognitive Impact and Efficacy

Trial Profile

Treatment of Spinal Cord Injury Patients for Neurogenic Bladder: an Open Label Pilot Study of Anticholinergic Agent vs. Mirabegron (MYRBETRIQ) to Evaluate Cognitive Impact and Efficacy

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 24 Dec 2018

At a glance

  • Drugs Mirabegron (Primary)
  • Indications Neurogenic bladder; Spinal cord injuries
  • Focus Therapeutic Use
  • Acronyms SCIMYR
  • Most Recent Events

    • 14 Dec 2018 Planned End Date changed from 31 Oct 2020 to 30 Nov 2020.
    • 14 Dec 2018 Planned primary completion date changed from 31 Oct 2019 to 30 Nov 2019.
    • 12 Nov 2018 Planned End Date changed from 31 Aug 2020 to 31 Oct 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top